Prior authorization runs on three inputs: a rule document the plan selected, a clinical file the prescriber assembles, and a reviewer who compares one against the other. Where the insurer and the pharmacy benefit manager belong to the same parent company, the governing rule may sit in a medical policy library or in a pharmacy drug list, and identifying which one applies comes before anything else.
Two rule libraries, and only one of them applies
Large carriers publish clinical policy documents describing when they consider a service or drug eligible under the medical benefit. Pharmacy benefit managers separately maintain drug lists with attached criteria for products dispensed under the pharmacy benefit. Aetna is a CVS Health company and CVS Caremark sits in the same group, so both libraries can carry the name of one corporate family while governing different rails.
Most weight-management prescriptions travel the pharmacy rail, which means the drug list criteria usually govern. That is a default rather than a rule, and confirming which rail a specific claim runs on prevents a prescriber’s office from filing against the wrong criteria set and waiting three weeks to learn it.
Selection sits with the plan sponsor
A benefit manager builds templates. It does not decide what an employer buys. A self-funded sponsor chooses which template to adopt, whether the weight-management category is included at all, and which optional utilization rules to switch on. The reviewer applying those rules works for the administrator; the rules themselves were purchased by someone else.
The consequence is that identical cards can carry different criteria. A criteria document circulating online may be a national template that no longer matches the version attached to a particular member. The authoritative copy is the one the plan supplies, and members can request it. That request is worth making before anything is filed, because it converts guesswork into a checklist.
| Document | What it is | Who maintains it | What it settles |
|---|---|---|---|
| Plan document or benefit summary | The contract of coverage | Plan sponsor or carrier | Whether the category exists |
| Drug list | Covered products and their conditions | Pharmacy benefit manager | Placement and required reviews |
| Criteria set | The questions a reviewer works through | Benefit manager, selected by sponsor | Approval or refusal |
| Medical policy bulletin | Carrier position on medical benefit items | The insurer | Requests on the medical rail |
| Approval notice | What was granted, and for how long | Reviewing organization | Product, quantity, end date |
| Denial notice | Reason and challenge instructions | Reviewing organization | What the next filing must answer |
How the request travels
The prescriber starts it. Most requests now move through electronic prior authorization built into prescribing software, which pulls the question set attached to the specific drug and plan and returns a determination faster than fax or telephone can. Where the electronic path is unavailable, a plan-specific form goes in directly.
Patients have one job at this stage, and it is not chasing status. Weight and height measurements, dated notes on earlier attempts and earlier medications, and any recorded weight-related condition either exist in the chart or they do not. A practice cannot submit what nobody wrote down, and gathering records from a previous physician is something only the patient can authorize.
What a reviewer works through
Criteria differ by plan and are revised, so any specific list quoted secondhand should be treated as unverified. The categories are stable even when the details are not: the labeled indication for the product requested, documentation the plan requires about history and measurements, and evidence of earlier therapy where a step requirement has been switched on.
Step therapy deserves separate mention because it is inconsistent by design. Health services research examining step protocols across plans found wide variation in how often they are applied and what they demand, including inside a single organization’s book of business, and separate work on Medicare Advantage plans found the same unevenness. A step refusal states that a preferred product has not been tried or documented as failed. It is not a verdict on the requested drug.
Obesity medicine has meanwhile been moving toward assessment that looks past a single measurement toward confirmed excess adiposity and its functional effects, while benefit criteria still run on figures a reviewer can locate in a note. That gap explains a good deal of the frustration on both sides of these files.
Timing, and what pending really means
Standard requests are generally decided within a few business days once complete information arrives, and expedited review exists where a delay would cause harm. The clock that counts starts when the plan holds a complete submission, not when the office first opened the form. An incomplete file can therefore sit for two weeks without any deadline being broken, which is why confirming receipt of a complete file beats calling for status.
An approval has an expiry date
Authorizations run for a fixed period and continuation is a fresh review rather than an automatic rollover. Reauthorization commonly asks for evidence of response and continued treatment. Nothing notifies the member, so the failure people hit most often is an expiry nobody diarized, discovered at a pharmacy counter on a refill day. A reminder set two months before the end date turns that into routine paperwork.
When the review closes for good
Where the exception and appeal routes are exhausted, or where the sponsor excluded the category and there was never a clinical review to win, the question becomes what the drug costs unaided. Manufacturer self-pay pricing keeps the approved product in play. Cash telehealth programs are cheaper monthly, and the posted figure matters less than the provider behind it, because supervision, dose adjustment and follow-up testing are what separate one program from the next. Compounded semaglutide, which many such programs dispense, is not an FDA-approved product, and the agency does not review compounded medicines for safety, effectiveness or quality before they reach patients.
That difference between programs is easy to see once the quotes are lined up. The same class of provider can post very different monthly totals depending on how it handles visits, dose changes and laboratory follow-up. Comparing what HealthRX, Ro and Hims and Hers each publish for Wegovy gives a clearer read than any single advertised price, which is why gathering a few quotes before committing tends to pay off.
Questions people ask
Can a member file the request instead of the prescriber?
Generally no. The submission depends on clinical documentation only the practice holds, and plans route these through prescriber channels. What a member can usefully do is confirm the plan received a complete file and request a copy of the criteria being applied, both of which move things along faster than status calls.
Does an approval fix what the drug costs?
No. Approval settles whether the plan pays anything. The amount owed still depends on list placement, deductible status and any coinsurance percentage. Someone can hold a valid authorization and still face a large January bill because the deductible reset on the first day of the plan year.
Is review applied to every weight-management drug?
Almost always, where the category is covered at all. Utilization controls are the standard tool for high-cost classes, and research measuring prescription response to those controls shows they change what actually gets dispensed. A plan covering this class with no review of any kind is the exception rather than the pattern.
Why do two people at the same company give different answers?
Because medical and pharmacy benefits run on separate systems with separate records, and staff answering each line can see only their own. Corporate affiliation between an insurer and a benefit manager does not merge those systems. Asking which rail a claim adjudicated on usually resolves the contradiction in one call.
